Gilead Sciences says Selonsertib, a new drug for treating NASH, a type of liver disease, failed Phase 3 trials.
Strong sales of key cancer treatment drug Keytruda are expected to continue to drive revenues and earnings.
Analysts have noted that the weed leader's momentum is set to burn higher moving forward.
In the interest of due diligence, we went and took a close look at the ground floor of the newest investment craze.
Allergan's textured breast implants have been linked to a rare form of cancer.
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Pfizer may have poked the bear.
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
Jim Cramer takes a look at the market.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.